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Abstract
Purpose Qigong as a complementary and alternative mo-
dality of traditional Chinese medicine is often used by
cancer patients to manage their symptoms. The aim of this
systematic review is to critically evaluate the effectiveness
of qigong exercise in cancer care.
Methods Thirteen databases were searched from their incep-
tions through November 2010. All controlled clinical trials
of qigong exercise among cancer patients were included.
The strength of the evidence was evaluated for all included
studies using the Oxford Centre for Evidence-based Medi-
cine Levels of Evidence. The validity of randomized con-
trolled trials (RCTs) was also evaluated using the Jadad
Scale.
Results Twenty-three studies including eight RCTs and fif-
teen non-randomized controlled clinical trials (CCTs) were
identified. The effects of qigong on physical and psychoso-
cial outcomes were examined in 14 studies and the effects
on biomedical outcomes were examined in 15 studies. For
physical and psychosocial outcomes, it is difficult to draw a
conclusion due to heterogeneity of outcome measures and
variability of the results in the included studies. Among
reviewed studies on biomedical outcomes, a consistent ten-
dency appears to emerge which suggests that the patients
treated with qigong exercise in combination with conven-
tional methods had significant improvement in immune
function than the patients treated with conventional methods
alone.
Conclusions Due to high risk of bias and methodological
problems in the majority of included studies, it is still too
early to draw conclusive statements. Further vigorously
designed large-scale RCTs with validated outcome measures
are needed.
Keywords Cancer . Qigong . Exercise . RCT. CAM
Introduction
As a major chronic illness and one of the leading causes of
mortality, cancer poses adverse and debilitating impacts on
the patients' functional capacity and quality of life. Cancer
patients often experience painful symptoms and side effects
following treatments such as surgery, chemotherapy, and
radiotherapy. An increasing use of complementary and al-
ternative medicine (CAM) by cancer patients as a supple-
ment to the mainstream Western medical interventions has
been evident in the literature [1–3]. Patients with cancer
usually employ CAM for promoting health and managing
symptoms experienced during active treatment and the pe-
riod of survivorship [4].
Qigong, a general term for a large range of traditional
Chinese energy exercises and therapies, is a form of tradi-
tional Chinese medicine (TCM) practice. It is popularly
practiced by a large number of people in Chinese commu-
nities. Basically, there are two categories of qigong: internal
qigong versus external qigong. Internal qigong or qigong
exercise is self directed and involves the use of movements,
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meditation, and control of breathing pattern. The gentle
movements and postures of the exercise are designed to
achieve a harmonious flow of energy (qi) in the body so
as to improve physical fitness and overall well-being. Ex-
ternal qigong is usually performed by a trained practitioner
using their hands to direct emitted “qi” energy onto the
patient's body in diagnosis and treatment of various dis-
eases. RCTs have shown efficacy for some TCM therapies
[5], but the efficacy of other complementary and alternative
modalities, particularly qigong, remains uncertain despite its
popularity among chronic patients. One earlier review of
qigong for cancer treatment did not differentiate between
internal and external qigong [6, 7]. However, the mecha-
nism of its effect is different for internal and external
qigong, so their efficacy may not be the same. One recent
review of qigong exercise for cancer treatment did not
examine the efficacy of qigong exercise on different health
outcomes critically and did not consider biomedical out-
comes [8, 9]. Thus, the primary objective of this review is
to examine the overall efficacy and effectiveness of qigong
exercise in cancer care, with a particular focus on different
health outcomes.
Methods
The following electronic databases were searched from their
respective inceptions through November 2010: The
Cochrane Central Register of Controlled Trials (CEN-
TRAL), PubMed/MEDLINE, The Cumulative Index to
Nursing and Allied Health Literature (CINAHL), Excerpta
Medica Database (Embase), Allied and Complementary
Medicine Database (AMED), Qigong and Energy Medicine
Database, China Journals Full-text Database—Medicine/
Hygiene Series, China Proceedings of Conference Full-text
Database, Chinese Master Theses Full-text Database, China
Doctor Dissertations Full-text Database, Electronic Theses
and Dissertation System (Taiwan), Taiwan Electronic Peri-
odical Services, and Index to Taiwan Periodical Literature
System. The search terms used for this review included:
qigong, qi-gong, qi gong, chi chung, chi gong, qi chung,
cancer, tumor, carcinoma, and neoplasm. Both traditional
and simplified Chinese translations of these terms were used
in Chinese databases. Reference lists of all included studies,
existing reviews, and other archives of the located publica-
tions were hand searched for further relevant studies.
All controlled clinical trials among cancer patients who
received qigong intervention alone or combined with other
treatments, either on an individual basis or as group ses-
sions, were included. RCTs were preferred and CCTs in-
cluding cohort studies and case–control studies were also
included to provide alternative evidence due to limited
number of RCTs in the field. Uncontrolled observational
studies were excluded. Due to the focus on internal qigong
in this systematic review, studies on external qigong were
excluded. For all included studies, the primary data from the
original sources were reviewed and analyzed.
All available evidence of the health benefits of qigong
exercise for cancer patients was considered. Specifically, the
outcome measures for this review included indicators of
physical health such as symptoms, measures of psychoso-
cial health such as quality of life, and biomedical outcomes.
For each included study, data were extracted by one main
researcher and then verified by another researcher. Any
discrepancies were resolved by discussion. The strength of
the evidence was evaluated for all the included studies using
the Oxford Centre for Evidence-based Medicine Levels of
Evidence [10]. These criteria grade the methodological rigor
of studies from level 1 or grade A (systematic review of
RCTs, 1a; individual RCT with narrow confidence interval,
1b) to level 5 or grade D (expert opinion). The quality and
validity of the included RCTs were also evaluated using the
Jadad Scale [11], which is based on three criteria: descrip-
tion of randomization, blinding, and patient attrition (the
score ranges from 0 to 5, the higher the better). This scale
has been continually used in systematic reviews.
Internal validity for all included controlled trials, including
selection bias, performance bias, detection bias, and attrition
bias, were assessed using the framework for methodological
quality recommended by Jüni et al. [12]. Risk of bias for the
included RCTs was also evaluated on the basis of the quality
of their randomization procedure and allocation concealment,
blinding, and incomplete outcome data assessment, as recom-
mended in the Cochrane Handbook [13].
Results
Our search returned 261 relevant references. Any studies that
were (1) not related to qigong or cancer, (2) not a clinical trial,
(3) not a controlled study, (4) studies on external qigong or
emitted “qi”, (5) studies with unparallel control design, (6)
case reports, or (7) duplicative publications were excluded.
Consequently, 23 studies including eight RCTs [14–21] and
fifteen CCTs [22–36], published between 1988 and 2010,
were identified for inclusion in this review. Of them, 14
studies examined the effects of qigong exercise on physical
and psychosocial outcomes and 15 studies examined the
effects on biomedical outcomes (including six studies on
both). Characteristics of the included studies on physical and
psychosocial outcomes are presented in Table 1, and the
studies on biomedical outcomes are presented in Table 2.
The samples in the included studies ranged from 20 to 229.
A two-armed, parallel group design was used in nearly all of
the included studies except two RCTs. One RCT [21] was
conducted with a three-armed parallel group design and
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another RCT [17] with a four-armed parallel group design.
The number of participants in each subgroup was reported in
most of the included studies, except two studies [25, 26] in
which only the number of total sample was reported. We
assumed that participants in the two studies were equally
allocated to each subgroup. Thus, the included studies on
physical and psychosocial outcomes covered 572 cancer
patients in qigong groups (ranging from 10 to 104) and 595
cancer patients in control groups (ranging from 10 to 136),
and the studies on biomedical outcomes covered 656 cancer
patients in qigong groups (ranging from 15 to 124) and 601
cancer patients in control groups (ranging from 15 to 105). Of
the 23 included studies, ten studies focused on single type of
cancer such as gastric cancer [18, 19, 23, 25, 27], adenocarci-
noma of cardia [17], hepatocellular carcinoma [16], breast
cancer [22, 29], and nasopharyngeal carcinoma [32]; others
employed a sample including multiple types of cancer.
Interventions employed in these studies included qigong
plus herbal medicine [19, 25, 33] or drugs [28], chemother-
apy [16, 18, 20, 22, 23, 29, 31], radiotherapy [32], usual
medical care [14, 15, 27, 30], or multiple therapies [24]. In a
study with three-armed parallel group design [21], the inter-
vention group with qigong exercise plus chemotherapy was
compared with two control groups (qigong exercise alone
and chemotherapy alone). In another study with a four-
armed parallel group design [17], the intervention group
with qigong exercise plus surgery and herbal medicine was
compared with three control groups (surgery plus chemo-
therapy, surgery plus herbal medicine, and surgery only).
Durations of qigong intervention ranged from 21 days to
5 years, with no longer than 2 months for six studies [15, 18,
21–23, 29], from 10 weeks to 6 months for nine studies [14,
16, 19, 24, 28, 30, 31, 33, 35], and as long as 5 years for
three studies [17, 26, 27]. Duration of intervention was not
reported in five studies [20, 25, 32, 34, 35].
The emerged physical and psychosocial outcomes (Table 3)
in these studies included self-perceived symptoms [15, 18–20,
22, 23, 25, 28], quality of life (QOL) [14–16, 19], psycholog-
ical distress [14, 16, 22, 24], survival rate [16, 17, 26], response
rate [18, 19], fatigue [14, 23], physical functioning [23], body
weight [28], and tumor size [19]. Biomedical outcomes (Ta-
ble 4) that emerged in these studies included “inflammatory
markers” (C-reactive protein) [14, 15], parameters of immunity
such as immunoglobulin and complements [25, 28, 32–35],
the numbers or the proportions of blood cells or their anti-
oxidize capacity [21, 27, 29–32, 34], and hepatic function [16].
Effects of interventions
Four RCTs [14–16, 19] examined the effect of qigong
exercise on QOL. Two studies showed that overall QOL
was improved significantly in the qigong group compared
with the control group [14, 19]. In two other studies, QOL
was not improved significantly in the qigong group com-
pared with controls [15, 16]. Four studies including two
RCTs [14, 16], and two CCTs [22, 24] evaluated the effects
of qigong exercise on psychological distress [22], mood
disturbance [14], anxiety, and depression [16, 24]. Only
one study [14] revealed that mood status was improved
significantly when compared with the control group receiv-
ing usual medical care (p<0.05).
Eight studies including three RCTs [15, 18, 20] and five
CCTs [19, 22, 23, 25, 28] assessed the effect of qigong
exercise on the improvement of symptoms among cancer
patients. All of the five CCTs generated a significant result.
Of the three RCTs, only one [19] indicated that fewer
participants in the qigong group suspended chemotherapy
due to symptoms compared to a control group (8% vs. 40%,
p<0.05). Results of two other RCTs showed that the differ-
ence for symptom improvement between the qigong group
and the control group was not statistically significant.
Two studies including one RCT [14] and one CCT [23]
examined the efficacy of qigong exercise in improving
fatigue among patients with various cancers. Results of both
studies indicated that fatigue in the qigong group was sig-
nificantly improved at post-intervention compared with the
control group. One of them [23] also examined the effect of
qigong exercise on physical functioning, and the results
demonstrated a significant difference between the two
groups in the level of difficulty with daily activities at
post-intervention after controlling for baseline variables.
Two RCTs examining the effect of qigong combined with
chemotherapy [18] or herbal medicine [19] on short-term
“response rate” among patients with late-stage gastric can-
cer did not show a statistically significant difference be-
tween the qigong group and the control group. However,
three studies including one RCT [17] and two CCTs [26, 27]
on long-term survival rate among cancer patients reported a
significant difference in the 5-year survival rate between
those practicing qigong and controls.
One RCT [19] examined the effect of qigong exercise plus
herbal medicine on tumor size in 40 elderly patients with late-
stage stomach cancer, who were either too old or too far along
in their diagnosis to undergo surgery. Tumor size was mea-
sured with objective measures such as X-ray, CT scan, biopsy,
and/or ultra-sound. No significant difference was found be-
tween the qigong group and a control group after 3 months of
intensive treatment. One CCT [28] evaluated the effect of
qigong exercise on the change of body weight among cancer
patients. At the end of the 3-month trial, body weight in-
creased more than 3 kg in half (50.5%) of participants in the
qigong group and one-eighth (13.3%) in the control group;
meanwhile, 5.4% in the qigong group and 30% in the control
group lost more than 3 kg in body weight.
Two RCTs by the same research team [14, 15] examined the
effect of qigong exercise on a primary biomarker of inflammation
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—serum C-reactive protein (CRP), which has been found in
several studies to be an independent predictor of cancer progno-
sis. In a pilot study [15], the results indicated no significant
difference in the level of CRP between the qigong group and a
control group at post-intervention. In a subsequent large-scale
study [14], the results indicated that inflammation was signifi-
cantly improved in the qigong group at the end of 10 weeks
intervention, compared with the control group with usual care
after controlling for baseline variables (p<0.05).
Seven studies [25, 28, 31–33, 35, 36] investigated the
impacts of qigong exercise for immune function with a great
variety of outcome parameters including phagocyte rate [28],
acid alpha-naphthyl acetate esterase (ANAE)—the determina-
tion of T lymphocytes [33, 35, 36], immunoglobulin A (IgA),
and immunoglobulin M (IgM) [32, 35], complement 3 [32],
and the rate of unscheduled DNA synthesis (UDS) in periph-
eral blood lymphocytes [31]. Overall, the results of these
studies demonstrated a favorable effect of qigong exercise
on immune function, except for two studies with no signifi-
cant improvement in the levels of IgA and IgM [32, 35].
Four studies [21, 27, 29, 32] assessed the effects of
qigong exercise on the numbers or the levels of components
in peripheral blood, and two additional studies [30, 34]
examined the anti-oxidize capacity of blood components.
All of these studies revealed a desirable result. One study
[16] testing the effect of qigong combined with transcatheter
arterial chemoembolization (TACE) on hepatic function in
patients with hepatocellular carcinoma indicated that no
significant improvement in hepatic function was found after
24 weeks intervention.
Table 3 Distribution of studies across physical and psychosocial outcomes
Outcomes Studies Design n (QG group) Duration Results
Quality of life (QOL): Oh et al. [14] RCT 54 10 weeks p<0.001
Oh et al. [15] RCT 15 5 weeks n.s.
Lam [16] RCT 13 24 weeks n.s.
Fu and Wang [19] RCT 22 3 months p<0.05
Symptoms Oh et al. [15] RCT 15 5 weeks n.s.
Fu and Zou [18] RCT 10 4 weeks n.s.
Lee et al. [22] CCT 32 21 days p<0.05
Hong [23] CCT 24/2 8 weeks p<0.05 after 4 weeks
p>0.05 after 8 weeks
Fu and Wang [19] RCT 22 3 months p<0.05
Fu [25] CCT 22 3 months p<0.05
Wang et al. [20] RCT 32 – p<0.05
Sun and Zhao [28] CCT 97 3 months p<0.01
Psychological well-being Oh et al. [14] RCT 54 10 weeks p<0.05
(mood disturbance)
Lee, et al. [22] CCT 32 21 days n s.
(psychological distress)
Wang and Ye [24] CCT 104 2.5–3.5 months n.s.
(anxiety and depression)
Lam [16] RCT 13 24 weeks n.s.
(anxiety and depression)
Physical functioning Hong [23] CCT 24/2 8 weeks p<0.01
Fatigue Oh et al. [14] RCT 54 10 weeks p<0.01
Hong [23] CCT 24/2 8 weeks p<0.01
Survival rate Fu et al. [17] RCT 50 5 years p<0.05
Peng et al. [27] CCT 20 5 years p<0.05
Zheng [26] CCT 100/2 5 years p<0.01
Response rate Fu and Zou [18] RCT 10 4 weeks n.s.
Fu and Wang [19] RCT 22 3 months n.s.
Tumor size Fu and Wang [19] RCT 22 3 months n.s.
Body weight Sun and Zhao [28] CCT 97 3 months p<0.05
QG qigong; RCT randomized controlled trial; CCT non-randomized controlled trial; n.s. no significance
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Risk of bias in included studies
Of the 23 included studies, only 8 are RCTs, and the 15
included CCTs may have a high risk of selection bias and
the strength of evidence for the results of these studies is
limited due to their non-randomized design. Of the eight
included RCTs, only three studies [14–16] described the
method of randomization, one study [16] described details
about allocation concealment, and three studies [14–16]
reported details of drop-outs and withdrawals that might
lead to exclusion of some particular patients. Other studies
did not describe their methods of sequence generation or
allocation concealment and drop-outs and were rated as
“unclear” for those domains within this review. Given the
nature of the qigong exercise intervention, blinding of par-
ticipants and intervention delivery was generally infeasible.
However, none of the included studies made an attempt to
blind the assessors. Thus, a risk for biases might be intro-
duced in most of the included RCTs.
These studies were conducted in Australia [14, 15], Korea
[23], Taiwan [22, 29], Hong Kong [16], and mainland China
[17–20, 24–28, 30–36]. Only four of them were published in
peer-review journals in English [14, 15, 22, 29], and two were
published in Chinese academic journals [24, 33]. Two studies
were unpublished theses [16, 23], and two other studies were
published in a book [18, 19]. The remaining thirteen studies
were presented in conferences on medical qigong without
detailed information provided [17, 20, 21, 25–28, 30–32,
34–36]. These studies had not undergone the process of peer
review, thus introducing to the potential for a number of biases.
Discussion
In this systematic review, the effectiveness of qigong exer-
cise on multiple health outcomes in supportive care to
cancer patients was examined comprehensively. To summa-
rize, 23 controlled trials including 8 RCTs and 15 CCTs
Table 4 Distribution of studies across biomedical outcomes
Outcomes Studies Design Biomedical outcomes n (QG group) Duration Results
Inflammatory marker Oh et al. [14] RCT Serum CRP 54 10 weeks p>0.05
Oh et al. [15] RCT Serum CRP 15 5 weeks p<0.05
Immune function Sun and Zhao [28] CCT Phagocytic rate 97 3 months p<0.05
Fu [25] CCT “Index of immunity” 40/2 n.r. p<0.01
Xu et al. [36] CCT ANAE 50 n.r. p<0.01
Qi [33] CCT ANAE 41 3 months p<0.01
Xu and Qi [35] CCT ANAE 40 3 months p<0.01
IgA, IgM p>0.05
InG, LAI, EA p<0.01
(pre- vs. post-)
Lo et al. [32] CCT C3 31 n.r. p<0.05
IgA, IgM, Ch50, CIC p>0.05
Ye et al. [31] CCT UDS 33 3 months p<0.05
Blood cells and
anti-oxidize
capacity
Yeh et al. [29] CCT WBC, RBC, Hb 32 21 days p<0.01
Luo and Tong [21] RCT WBC, RBC, Hb 25 60 days p<0.05
Peng et al. [27] CCT WBC, RBC, Hb 20 5 years p<0.05
Lo et al. [32] CCT WBC, RBC, Hb 31 n.r. p<0.05
Xu et al. [34] CCT Cu-Zn SOD 124 n.r. p<0.01
Yu [30] CCT SOD, LPO 20 6 months p<0.01
Hepatic function Lam [16] RCT AFP, ALP, ALT, AST, albumin,
globulin, total protein
13 24 weeks n. s.
QG qigong; RCT randomized controlled trial; CCT non-randomized controlled clinical trial
n.r. not reported; n.s. no significance
AFPAlpha-fetoprotein; ALP alkaline phosphatase; ALT alanine aminotransferase; ANAE acid alpha- naphthyl acetate esterase (the determination of
T lymphocytes); AST aspartate aminotransferase; CH50 hemolytic complement 50; C3 complement 3; CIC circulating immune complexes; CRP C-
reactive protein; CT computed tomography; Cu-Zn SOD cupro-zino superoxide dismutase activity in the red blood cells (RBC); EA active E rosette
formation; Hb serum hemoglobin; HBV-DNA hepatitis B DNA; IgA immunoglobulin A; IgG immunoglobulin G; IgM immunoglobulin M; INR
international normalized ratio; LAI leukocyte adherence inhibition test; PL platelet; LPO lipoperoxide; RBC red blood cell; SDS McCorkle and
Young's symptom distress scale; SOD superoxide dismutase; TACE transcatheter arterial chemoembolization; TLC T-lymphocyte conversion;WBC
white blood cell
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were included in this review. Five RCTs suggested favorable
effects of qigong exercise on the improvement of symptoms
[19, 20], inflammation [14], QOL, and mood disturbance
[14], the increase of the number or the levels of components
in peripheral blood [21], and the increase of the 5-year
survival rate in cancer patients [17]. The other three RCTs
showed no significant differences in outcome measures
between the intervention group and the control group [15,
16, 18]. Almost all of the included CCTs, except one [24],
showed a favorable effect of qigong exercise on health out-
comes in cancer care.
There is a great variability in outcome measures in the
studies examined in this review. Specifically, 14 studies
have examined the effects of qigong on physical and psy-
chosocial outcomes, and 15 studies have examined the
effects of qigong on biomedical outcomes among cancer
patients. Among physical and psychosocial outcomes, im-
provement of symptoms is the most frequently used out-
come measure in the included studies, followed by
psychological distress, QOL, survival rate, and fatigue. Oth-
er outcomes less commonly employed in these studies in-
clude physical functioning, response rate, tumor size, and
body weight. Due to the variability of the results of the
included studies and a high risk of bias in most of the
included studies which may have led to false-positive
results, it is difficult to draw a conclusion about the efficacy
and the effectiveness of qigong exercise on physical and
psychosocial outcomes in supportive care to cancer patients.
Two outcomes that may see benefit are symptoms (includ-
ing fatigue) and QOL, even though a few studies on QOL
[15, 16] and symptoms [15, 18] have not demonstrated a
desirable effect of qigong exercise in cancer care, possibly
due to very limited sample size in the studies. With regard to
the studies on biomedical outcomes examined in this review,
it seems that there is a consistent tendency whereby the
patients treated with qigong therapy in combination with
conventional methods enjoyed significant improvements in
immune function than the patients treated with conventional
methods alone.
A careful examination of the included studies reveals
some methodological flaws that exist in current studies on
qigong intervention. The first limitation is sample size. Of
the 23 included studies, seven studies were based on a total
sample of less than 50 [15, 18, 19, 23, 25, 27, 30] with the
smallest number being 20 participants. Nine studies were
conducted with a total sample of more than 50 but less than
100 [16, 20–22, 29, 31–33]. Small sample size in these
studies might lead to a type II error for their results. More-
over, sample size in nearly all of the included studies was
not justified except one study [16] in which the calculation
of sample was presented.
Second, the intervention designs in the included studies
are problematic. In nearly all of the included prospective
studies, qigong exercise was preferentially provided to the
intervention groups as an additional group therapeutic mo-
dality to the usual medical care or chemotherapy that was
applied to both intervention group and control group,
whereas the control groups did not have a matched number
of social contact hours with co-participants. Thus, these
studies might be subject to potential risk of performance
bias, and a placebo effect might have occurred in patients
who enjoyed participation in group activities and the contact
with other persons. This design limitation needs to be
addressed in future studies.
Heterogeneity in the quality and the dosage of qigong
intervention across the included studies is another problem.
Of the 23 included studies, the style of qigong exercise was
reported only in nine studies [14–16, 21–23, 27, 29, 30],
which varied greatly. Practically, many styles or forms of
qigong exercise, e.g., Guo-Lin Qigong, Chinese Taiji Five-
Element Qigong, and Chan-Chuang Qigong, have been de-
veloped. Basically, qigong exercise can be divided into dif-
ferent types including meditative qigong (quiescent qigong
known as jing gong in Chinese), dynamic qigong (active
qigong known as dong gong in Chinese), and a combination
of the two (jing dong gong). The intensity of exercise is often
different for these types of qigong exercise. In some studies, a
term “medical qigong” was used and was defined as “the
prescription of qigong recommended or designed by amedical
practitioner to improve the health of patient” [14, 15]. Accord-
ing to this definition, the form and the intensity of exercise are
not standardized yet. Moreover, the frequency of qigong
exercise was reported only in less than half of the studies
examined in this review, with a great disparity. Therefore,
there is a great variability of the dosage and quality of qigong
exercise across the included studies, which also make it diffi-
cult to compare and synthesize the results of these studies. It
will be better to transform the intensity of qigong exercise to
metabolic equivalents (METs), which is a scientific and stan-
dardized measure of the intensity of physical exercise [37], in
future studies so as to increase the comparability of the results
across different studies.
Lastly, a high risk of bias exists in most of the included
studies. Of the 23 included studies, the methods of random-
ization were described in only three studies [14–16], details
about allocation concealment were presented in only one
study [16], and the proportion of drop-outs and withdrawals
were reported in only three studies [14–16]. Other studies
described neither their methods of sequence generation or
allocation concealment nor the proportion of drop-outs or
withdrawals, and the evidence was thus weakened for the
results of these studies. The fifteen included CCTs, most of
them were poor-quality cohort or case–control studies, were
subject to high risk of selection bias, making that the syn-
thesis and generalization of the results should be treated
with caution.
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Previous reviews have suggested three possible mecha-
nisms (improvement of immune functions, improvement of
microcirculation, and increase in pain threshold) of the
effects of qigong exercise for cancer patients [6, 7]. How-
ever, the findings of the current review suggest that there is a
lack of evidence to date to support the postulations that
qigong exercise can raise the pain threshold in patients with
cancer. Although most of the included studies on biomedical
outcomes suggest that qigong exercise may lead to an im-
provement in immune function among cancer patients, but it
is still unclear whether the improvement of immune function
is sufficient to provide definitive benefits to the patients,
since most of the included studies focus on antibody re-
sponse or the enumerative measures of immunity in periph-
eral blood, and the studies on functional measures or cell-
mediated cancer-specific immunity, which is the key com-
ponent of immunity for cancer cells, are very limited. Given
the heterogeneity in outcome measures and the limited
number of RCTs in the field, better designed studies and
scientific evidences are needed to test the statement that
qigong therapy may improve cancer patients’ immune
functions.
Overall, study quality was poor for most of the studies
examined in this review. Of the 23 included studies, only
three studies could be ranked “A” in the levels of evidence;
eleven studies were ranked “B” and nine studies were
ranked “C”. Jadad scale scores for the eight included RCTs
ranged from 1 to 3, with a value of 1 for five RCTs.
Therefore, studies with higher quality are warranted in the
future.
Several limitations may exist in the current review. As
with most systematic reviews, there is potential incomplete-
ness of the evidence reviewed. Another limitation may be
related to selective publishing and reporting in the literature,
which is also a major cause of bias. In addition, we were
unable to perform meta-analyses due to the limited number
of RCTs and heterogeneity of outcome measures in the
included studies.
Conclusions
Due to limited number of RCTs in the field and methodo-
logical problems and high risk of bias in the included
studies, it is still too early to reach a conclusion about the
efficacy and the effectiveness of qigong exercise as a form
of health practice adopted by the cancer patients during their
curative, palliative, and rehabilitative phases of the cancer
journey. Since qigong exercise is preferred and widely prac-
ticed among patients with various cancers in China and
Asia, further well designed large-scale placebo-controlled,
randomized studies with validated outcome measures are
particularly needed.
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